LPS | LPS+PMB | |
---|---|---|
Genes | Fold change | Fold change |
Upregulated genes | ||
Baculoviral IAP repeat containing 3 (BIRC3) | 8.4* | 1.5 |
Chemokine (C-C motif) ligand 3 (CCL3) | 13.6** | 1.1 |
Chemokine (C-C motif) ligand 5 (CCL5) | 3.2 | 1.2 |
Cluster of differentiation 14 (CD14) | 3.0 | 1.2 |
Chemokine (C-X-C motif) ligand 1 (CXCL1) | 48.9** | 1.7 |
Chemokine (C-X-C motif) ligand 2 (CXCL2) | 92.4** | 3.5 |
Interleukin 1 beta (IL1β) | 15.1** | 1.8 |
Interleukin 6 (IL6) | 620.2* | 7.3 |
Interleukin 8 (IL8) | 14.1** | 1.8* |
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (NFKBIA) | 3.0 | 1.3 |
Receptor-interacting serine-threonine kinase (RIPK2) | 2.7** | 1.0 |
Tumor necrosis factor (TNF) | 16.5* | 1.4 |
Downregulated genes | ||
Deleted in malignant brain tumours 1 (DMBT1) | 2.5 | 1.0 |
Mitogen-activated protein kinase 14 (MAPK14) | 2.5 | 0.9 |
Proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1) | 2.9 | 0.9 |
Cannabinoid receptor 1 (CNR1) | 8.7*** | 0.5* |
Cannabinoid receptor 2 (CNR2) | 16.5* | 1.2 |
*p<0.05, **p<0.01, ***p<0.001 vs non-treated cells.
IAP, Inhibition of apoptosis; LPS, lipopolyshaccaride; PMB, polymixin B.